ATE131493T1 - Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase - Google Patents

Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase

Info

Publication number
ATE131493T1
ATE131493T1 AT90306037T AT90306037T ATE131493T1 AT E131493 T1 ATE131493 T1 AT E131493T1 AT 90306037 T AT90306037 T AT 90306037T AT 90306037 T AT90306037 T AT 90306037T AT E131493 T1 ATE131493 T1 AT E131493T1
Authority
AT
Austria
Prior art keywords
pro
cys
polypeptides
lys
gly
Prior art date
Application number
AT90306037T
Other languages
English (en)
Inventor
Enno Prof Christophers
Jens-Michael Dr Schroder
David Dr Pioli
Oliver Dr Wiedow
Michael Derek Dr Edge
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898913349A external-priority patent/GB8913349D0/en
Priority claimed from GB898913346A external-priority patent/GB8913346D0/en
Priority claimed from GB898921613A external-priority patent/GB8921613D0/en
Priority claimed from GB898924717A external-priority patent/GB8924717D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Application granted granted Critical
Publication of ATE131493T1 publication Critical patent/ATE131493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90306037T 1989-06-09 1990-06-04 Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase ATE131493T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB898913349A GB8913349D0 (en) 1989-06-09 1989-06-09 Polypeptides
GB898913346A GB8913346D0 (en) 1989-06-09 1989-06-09 Polypeptide analogues
GB898921613A GB8921613D0 (en) 1989-09-25 1989-09-25 Polypeptides-1st update
GB898924717A GB8924717D0 (en) 1989-11-02 1989-11-02 Polypeptides

Publications (1)

Publication Number Publication Date
ATE131493T1 true ATE131493T1 (de) 1995-12-15

Family

ID=27450350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90306037T ATE131493T1 (de) 1989-06-09 1990-06-04 Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase

Country Status (16)

Country Link
US (4) US5464822A (de)
EP (1) EP0402068B1 (de)
JP (1) JP2989853B2 (de)
AT (1) ATE131493T1 (de)
AU (1) AU636148B2 (de)
CA (1) CA2018592C (de)
DE (1) DE69024104T2 (de)
DK (1) DK0402068T3 (de)
ES (1) ES2080800T3 (de)
FI (1) FI106471B (de)
GR (1) GR3018401T3 (de)
IE (1) IE70520B1 (de)
IL (1) IL94602A (de)
NO (1) NO177716C (de)
NZ (1) NZ233974A (de)
PT (1) PT94326B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
US5162348A (en) * 1990-05-24 1992-11-10 Imperial Chemical Industries Plc Treatment of cystic fibrosis
ES2129401T3 (es) * 1990-05-24 1999-06-16 Zeneca Ltd Uso de un compuesto terapeutico para el tratamiento de bronquitis.
IE911697A1 (en) * 1990-05-24 1991-12-04 Zeneca Ltd Therapeutic agent
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
US8606851B2 (en) 1995-06-06 2013-12-10 Wayport, Inc. Method and apparatus for geographic-based communications service
US5835061A (en) 1995-06-06 1998-11-10 Wayport, Inc. Method and apparatus for geographic-based communications service
EP0834556A1 (de) * 1996-09-25 1998-04-08 Academisch Ziekenhuis Leiden Verfahren zur Zellkultivierung
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7041787B2 (en) * 2000-12-29 2006-05-09 Kimberly-Clark Worldwide, Inc. Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
US6600057B2 (en) 2000-12-29 2003-07-29 Kimberly-Clark Worldwide, Inc. Matrix metalloproteinase inhibitors
US20030119073A1 (en) * 2001-12-21 2003-06-26 Stephen Quirk Sensors and methods of detection for proteinase enzymes
EP1476573B1 (de) 2002-01-28 2010-01-06 Ambion, Inc. Für den nachweis von nukleinsäuren kompetente biologische rohderivate
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
CA2524626A1 (en) * 2003-05-07 2004-11-18 Vib Vzw The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells
US20090163409A1 (en) * 2005-05-16 2009-06-25 Ball T Blake Trappin-2 (elafin) inhibits HIV
US7964350B1 (en) 2007-05-18 2011-06-21 Applied Biosystems, Llc Sample preparation for in situ nucleic acid analysis
EP2955233A1 (de) 2008-12-19 2015-12-16 Life Technologies Corporation Proteinase K Inhibitore, Verfahren und Zusammensetzungen davon
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
EP4452303A4 (de) * 2021-12-20 2025-11-12 Tiakis Biotech Ag Verwendung von elafin bei der behandlung von covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
DE69032025T2 (de) * 1989-02-23 1998-05-20 Blood Res Center Menschlicher elastase-inhibitor
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff

Also Published As

Publication number Publication date
US6245739B1 (en) 2001-06-12
DE69024104D1 (de) 1996-01-25
US6893843B2 (en) 2005-05-17
NZ233974A (en) 1993-05-26
CA2018592C (en) 2002-08-27
NO902444D0 (no) 1990-06-01
NO902444L (no) 1990-12-10
EP0402068B1 (de) 1995-12-13
AU636148B2 (en) 1993-04-22
IL94602A0 (en) 1991-04-15
IL94602A (en) 1996-06-18
DE69024104T2 (de) 1996-06-13
FI902880A0 (fi) 1990-06-08
AU5680890A (en) 1990-12-13
IE902006L (en) 1990-12-09
IE70520B1 (en) 1996-12-11
ES2080800T3 (es) 1996-02-16
US20020187535A1 (en) 2002-12-12
PT94326B (pt) 1997-01-31
US5464822A (en) 1995-11-07
EP0402068A1 (de) 1990-12-12
PT94326A (pt) 1991-02-08
JP2989853B2 (ja) 1999-12-13
GR3018401T3 (en) 1996-03-31
JPH03148299A (ja) 1991-06-25
NO177716C (no) 1995-11-08
FI106471B (fi) 2001-02-15
CA2018592A1 (en) 1990-12-09
US20060068480A1 (en) 2006-03-30
DK0402068T3 (da) 1996-04-22
NO177716B (no) 1995-07-31

Similar Documents

Publication Publication Date Title
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
DK0502036T3 (da) Latens-associeret peptid og anvendelser herfor
DE3584579D1 (de) Herstellung von polypeptiden mit human-gammainterferon-aktivitaet.
AU2308992A (en) Cysteine depleted il-6 muteins
AU2002307510A1 (en) Cytokine protein family
DE68917837D1 (de) Peptid-Verbindungen.
AU1384995A (en) Human circulating cytokine cc-1
CA2011008A1 (en) Egf variants and pharmaceutical use thereof
CA2118498A1 (en) A novel anti-neoplastic cytokine
ATA264487A (de) Homogene, rekombinante immun-interferonfragmente
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
CA2078000A1 (en) Neutrophil stimulating peptides
ATE94168T1 (de) Peptide.
ES2066897T3 (es) 5,11-dihidro-6h-pirido(2,3-b)(1,4)benzodiazepin-6-onas y -tionas y su uso en la prevencion o el tratamiento del sida.
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
JPS6429A (en) Antiviral agent
AU7052291A (en) Genetic protection of animals against infection by the bovine leukemia virus, and provirus and recombinant virus derived from this virus
CA2090121A1 (en) Uses of colony stimulating factor-1

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time